As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...